Advertisement

Reactions Weekly

, Volume 1770, Issue 1, pp 28–28 | Cite as

Alemtuzumab/idelalisib/rituximab

Various toxicities: case report
Case report
  • 24 Downloads

Reference

  1. Patil N, et al. Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors. British Journal of Haematology 186: e80-e82, No. 4, Jan 2019. Available from: URL: http://doi.org/10.1111/bjh.15912 - United Kingdom

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations